CCL18 (C-C Motif Chemokine Ligand 18)

We validated MAPK10 promoter hypermethylation and CCL18 overexpression as prognostic biomarkers in ABC DLBCL. These findings, derived from integrative transcriptomic and immunogenomic profiling, provide clinically relevant insights into disease biology and support biomarker-guided strategies for precision treatment in aggressive B-cell lymphomas.

Conclusion SLC1A5 serves as an independent prognostic biomarker in melanoma. Its overexpression may shape an immunesuppressive microenvironment by dysregulating immune molecules expression and cellular infiltration, ultimately facilitating immune escape and malignant progression.

Our scRNA-seq analyses revealed significant alterations in the tumor microenvironment following GCP therapy: tumor-infiltrating macrophages underwent a distinct antitumor phenotypic shift, transitioning from M2 toward M1 polarization; concurrently, CD8+ T cells exhibited enhanced costimulatory signaling characterized by CD81 upregulation and malignant cells demonstrated diminished immune escape characteristics alongside heightened activity in immune response-related pathways. Our preliminary findings reveal a generally reactivated antitumor immune response in ICC following GCP therapy, which could partly illuminate the enigmatic black box of intra-tumoral cellular states associated with treatment response.

QJZG effectively improved renal injury in SLE by reducing inflammation and modulating the AMPK/ULK1 signalling pathway to suppress M1 macrophage polarisation.

These findings suggest that BALF macrophages and CCL18 protein levels are increased in patients with CIP and associate with greater CIP severity. Additionally, CCL18 promotes lung inflammation in mice that mimics human CIP, suggesting a causal role for CCL18 in CIP.

The above comprehensive analyses suggest that CXCL13 may serve as a potential prognostic biomarker for UCEC, specifically for early-stage UCEC.

Through the integration of clinical, experimental, and computational analyses, potential therapeutic targets and prognostic biomarkers were identified that may help improve clinical outcomes. Future studies should focus on the functional assays of identified genes both in vitro and in vivo.

Furthermore, G3I-treated M1 macrophages inhibit tumor cell proliferation and enhance macrophage phagocytic activity as well as M2 macrophages decrease tumor migration. These findings suggest that G3I regulates the balance of macrophage polarization in the tumor microenvironment, and enhances the phagocytic and microbicidal activities of macrophages, indicating its potential as a novel therapeutic application in cancer treatment offering a potential breakthrough in targeting immune modulation and improving anti-tumor responses.

© 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland

CCL18 shows strong prognostic and immunological relevance in BRCA, while EGF appears to play a broader oncogenic role. Hypomethylation of both genes may drive their aberrant expression and involvement in tumor progression.